Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Apr 1;8(4):e250398.
doi: 10.1001/jamanetworkopen.2025.0398.

Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial

Yo Han Jung  1   2 , Tae-Jin Song  3   4 , Jinkwon Kim  5 , Hee-Kwon Park  6 , Sang Won Han  7 , Young Dae Kim  8 , Jong-Ho Park  9 , Jae-Kwan Cha  10 , Hyun Young Park  11 , Sung-Il Sohn  12 , Sungwook Yu  13 , Jun Hong Lee  14 , Dong Hoon Shin  15 , Eung-Gyu Kim  16 , Hye Sun Lee  17 , Kyung-Yul Lee  1   2 ; PLATELET Trial Investigators
Collaborators, Affiliations
Clinical Trial

Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial

Yo Han Jung et al. JAMA Netw Open. .

Abstract

Importance: Cytochrome P450 2C19 (CYP2C19) genotypes influence the antiplatelet effectiveness of clopidogrel by affecting its conversion to its active metabolite. However, evidence from prospective trials regarding the effects of CYP2C19 genotypes on the role of clopidogrel preventing cardiovascular events among patients with acute ischemic stroke remains limited.

Objective: To investigate the association of the CYP2C19 genotypes with the clinical prognosis of patients with acute ischemic stroke treated with clopidogrel.

Design, setting, and participants: A prospective, nonrandomized clinical trial was conducted from September 1, 2019, to January 27, 2023, at 37 clinical sites in South Korea. Patients who received clopidogrel within 72 hours of experiencing an acute ischemic stroke were included.

Interventions: Patients were classified using CYP2C19 genotyping into carrier and noncarrier of CYP2C19 loss-of-function (LOF) allele. Clopidogrel treatment was maintained throughout the study period.

Main outcomes and measures: The primary outcome was the difference in the risk of cardiovascular events (including ischemic or hemorrhagic stroke, myocardial infarction, or cardiovascular death) within 6 months after an ischemic stroke between patients who were carriers or noncarriers of the CYP2C19 LOF allele. The primary safety outcomes were the differences in all-cause mortality and the occurrence of major bleeding. Intention-to-treat analysis was performed.

Results: Overall, 2925 patients were enrolled in the PLATELET trial. The mean (SD) age of the participants was 65.3 (12.4) years, and 1928 (66.3%) were men. Among these patients, 15 were excluded. Of the remaining 2910 patients, 61.3% were classified as poor or intermediate metabolizers and 38.7% as extensive metabolizers. The primary outcome occurred more frequently in carriers of the LOF CYP2C19 allele than in noncarriers (2.7% [49 of 1785] vs 1.6% [18 of 1125]; log-rank P = .048). No significant differences were observed between CYP2C19 LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; P = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; P = .27).

Conclusions and relevance: In this prospective nonrandomized clinical trial, carriers of the CYP2C19 LOF allele genotype exhibited a higher likelihood of experiencing cardiovascular events.

Trial registration: ClinicalTrials.gov Identifier: NCT04072705.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr J. Kim reported receiving grants from Chong Kun Dang Pharmaceutical and Myung In Pharmaceuticals outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Cumulative Incidence Plot for the Primary Outcomes
Figure 2.
Figure 2.. Cumulative Incidence Plot for the Safety Outcomes
See this image and copyright information in PMC

References

    1. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. . 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375 - DOI - PubMed
    1. Pereira NL, Rihal CS, So DYF, et al. . Clopidogrel pharmacogenetics. Circ Cardiovasc Interv. 2019;12(4):e007811. doi:10.1161/CIRCINTERVENTIONS.119.007811 - DOI - PMC - PubMed
    1. Wang Y, Zhao X, Lin J, et al. ; CHANCE investigators . Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016;316(1):70-78. doi:10.1001/jama.2016.8662 - DOI - PubMed
    1. Xie X, Johnston SC, Wang A, et al. . Association of CYP2C19 loss-of-function metabolizer status with stroke risk among Chinese patients treated with ticagrelor-aspirin vs clopidogrel-aspirin. JAMA Netw Open. 2023;6(6):e2317037. doi:10.1001/jamanetworkopen.2023.17037 - DOI - PMC - PubMed
    1. Oh IY, Park KW, Kang SH, et al. . Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart. 2012;98(2):139-144. doi:10.1136/hrt.2011.227272 - DOI - PubMed

Publication types

Associated data

LinkOut - more resources